Erratum: Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing (Genetics in Medicine (2001) 3(2) (139–148), (S1098360021008807), (10.1097/00125817-200103000-00009));American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing

Genetics in Medicine

Volumn 3, Issue 2, 2001, Pages 139-148

  Grody, Wayne W ^a   Griffin, John H ^a   Taylor, Annette K ^a   Korf, Bruce R ^a   Heit, John A ^a  

^a American College of Medical Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; HEPARIN; HOMOCYSTEINE; LUPUS ANTICOAGULANT; ORAL CONTRACEPTIVE AGENT; PROCOAGULANT; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ALLELE; ANTICOAGULATION; BLOOD CLOTTING DISORDER; COLLEGE; CONSENSUS SEQUENCE; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; METHODOLOGY; ORAL CONTRACEPTION; PREGNANCY; QUALITY CONTROL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; UNITED STATES; VEIN THROMBOSIS;

EID: 0035746675     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/s41436-021-01108-x     Document Type: Erratum

References (79)

1. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based cohort study
2. The factor V R506Q and prothrombin 20210G→A mutations as independent risk factors for venous thromboembolism: A population-based case-control study
3. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study
4. Factor V. Leiden and other coagulation factor mutations affecting thrombotic risk
5. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis
6. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
7. Resistance to activated protein C as a basis of venous thrombosis
8. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia
9. Mutations in blood coagulation factor V associated with resistance to activated protein C
10. Association of idiopathic venous thromboembolism with a single point-mutation at Arg506 of factor V
11. Activated protein C resistance caused by Arg506Gln mutation in Factor Va
12. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
13. The mechanism of inactivation of human factor V and human factor Va by activated protein C
14. Characterization of the molecular defect in factor V-R506Q
15. 506-factor V
16. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
17. Activated protein C resistance and factor V Leiden mutation are independent risk factors of venous thromboembolism
18. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening
19. The prevalence of the factor V Leiden mutation in four distinct American ethnic populations
20. Venous thrombosis due to poor anticoagulant response to activated protein C
21. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
22. The lupus anticoagulant/antiphospholipid syndrome
23. Modified APC resistance assay for patients on oral anticoagulant
24. Activated protein C resistance: A comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation
25. The long-term clinical course of acute deep venous thrombosis
26. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study
27. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
28. The duration of oral anticoagulation therapy after second episode of venous thromboembolism
29. The risk of recurrent thromboembolism in patients with an Arg506-Gln mutation in the gene for Factor V (Factor V Leiden)
30. Probability of recurrence of thrombosis in patients with and without factor V Leiden
31. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
32. Antithrombotic therapy for venous thromboembolism
33. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
34. Management of patients with hereditary defects predisposing to thrombosis including pregnant women
35. Update on thrombophilia
36. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A mutation
37. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota
38. Role of the factor V R506Q mutation in venous thromboembolism
39. Heritable coagulopathies in pregnancy
40. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss
41. Inherited thrombophilia and pregnancy loss
42. The treatment of thrombosis during pregnancy
43. Increased frequency of genetic thrombophilia in women with complications of pregnancy
44. The factor V Leiden mutation may predispose women to severe preeclampsia
45. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation
46. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
47. Prevalence of factor V Leiden and prothrombin variant F20210A in patients aage <50 years with no significant stenosis at angiography three to four weeks after myocardial infarction
48. The prevalence of poor anticoagulant response to activated protein C among patients suffering from stroke or venous thrombosis and among healthy subjects
49. Smoking and use of oral contraceptives: Impact on thrombotic diseases
50. Combined oral contraceptives, smoking, and cardiovascular risk
51. Oral contraceptives and screening for factor V Leiden
52. Activated protein C resistance and thrombosis
53. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis
54. Factor V Leiden. Should we screen oral contraceptive users and pregnant women?
55. Coexistence of hereditary homocystinuria and factor V Leiden: Effect on thrombosis
56. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism
57. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency
58. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families
59. Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation
60. Thrombosis in the young: Epidemiology and risk factors. A focus on venous thrombosis
61. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR
62. Simultaneous polymerase chain reaction restriction fragment length polymorphism identification of the factor V Leiden allele and the prothrombin 20210A mutation
63. Non-PCR-dependent detection of the factor V Leiden mutation from genomic DNA using a homogeneous invader microtiter plate assay
64. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
65. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
66. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives
67. Prothrombin G20210A mutation in a child with spinal cord infarction
68. Hyperhomocysteinemia. Pathogenesis, clinical significance, laboratory assessment, and treatment
69. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease
70. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The atherosclerotic risk in communities (ARIC) study
71. Homocysteine and vitamins in cardiovascular disease
72. Plasma homocysteine in venous thromboembolism
73. Plasma homocysteine levels in patients with deep venous thrombosis
74. Factor V Arg306→ Thr (factor V Cambridge) and factor V Arg306→Gly mutations in venous thrombotic disease
75. A novel mutation of the factor V gene in Hong Kong Chinese
76. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (Factor V Leiden)
77. The HR2 haplotype of factor V: Effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis
78. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V
79. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C